Mylan’s (MYL) “Buy” Rating Reiterated at BTIG Research
Mylan Inc. (NASDAQ:MYL)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a research note issued on Tuesday. They presently have a $55.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 52.52% from the stock’s current price.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research lowered Mylan from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Leerink Swann upped their target price on Mylan from $51.00 to $55.00 and gave the stock an “outperform” rating in a research note on Monday, August 15th. TheStreet raised Mylan from a “hold” rating to a “buy” rating in a research note on Friday, August 12th. Bank of America Corp. reaffirmed a “buy” rating and issued a $70.00 target price on shares of Mylan in a research note on Wednesday, August 24th. Finally, Wells Fargo & Co. reaffirmed a “market perform” rating and issued a $44.00 target price on shares of Mylan in a research note on Thursday, August 25th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Mylan presently has an average rating of “Buy” and a consensus target price of $52.83.
Mylan (NASDAQ:MYL) traded down 1.85% during mid-day trading on Tuesday, reaching $36.06. 3,698,152 shares of the company’s stock traded hands. Mylan has a 12 month low of $33.60 and a 12 month high of $55.51. The company has a 50 day moving average price of $37.27 and a 200-day moving average price of $42.19. The stock has a market cap of $19.30 billion, a P/E ratio of 72.26 and a beta of 1.10.
Mylan (NASDAQ:MYL) last released its earnings results on Wednesday, November 9th. The company reported $1.38 EPS for the quarter, missing the Zacks’ consensus estimate of $1.45 by $0.07. The business had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.12 billion. Mylan had a return on equity of 22.04% and a net margin of 2.50%. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.43 earnings per share. On average, analysts anticipate that Mylan will post $4.76 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Nuveen Asset Management LLC boosted its position in shares of Mylan by 22.5% in the first quarter. Nuveen Asset Management LLC now owns 36,195 shares of the company’s stock worth $1,678,000 after buying an additional 6,636 shares during the period. LPL Financial LLC boosted its position in shares of Mylan by 21.8% in the first quarter. LPL Financial LLC now owns 45,698 shares of the company’s stock worth $2,098,000 after buying an additional 8,170 shares during the period. Arizona State Retirement System boosted its position in shares of Mylan by 2.3% in the first quarter. Arizona State Retirement System now owns 111,808 shares of the company’s stock worth $5,182,000 after buying an additional 2,500 shares during the period. Integrated Investment Consultants LLC bought a new position in shares of Mylan during the second quarter worth approximately $145,000. Finally, Park National Corp OH boosted its position in shares of Mylan by 0.5% in the second quarter. Park National Corp OH now owns 5,875 shares of the company’s stock worth $254,000 after buying an additional 27 shares during the period. Institutional investors and hedge funds own 60.29% of the company’s stock.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan Inc. and related stocks with our FREE daily email newsletter.